Dr. Soliman Abdel Kader Fakeeh Hospital Company (4017) Fair Value & Analysis

Healthcare · SA · Market cap 7.9B SAR

What matters now

• The price sits above even our optimistic bull case (26.81 SAR). The favourable scenario is already priced in.
• Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.

Price vs Fair Value (12 months)

12‑month range 28.70 SAR – 42.22 SAR · fair‑value band 16.09 SAR – 26.81 SAR · the 34.94 SAR price screens above the 21.45 SAR fair value. As of Jul 31, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Dr. Soliman Abdel Kader Fakeeh Hospital Company (4017) currently trades at 34.94 SAR, while our model-based Fair Value estimate is 21.45 SAR, implying the stock looks roughly 38.6% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Dr. Soliman Abdel Kader Fakeeh Hospital Company generated revenue of 3.1B SAR at a net margin of 8.2%. Revenue grew 3.3% year over year. It earns a return on equity of 5.9%. Net debt stands at 737M SAR. Fundamentals as of Jul 31, 2026

Our scenario range runs from 16.09 SAR (bear case) to 26.81 SAR (bull case); at 34.94 SAR, the current price sits above that range. The share trades about 18% below its 52-week high and 30% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 4% fair-value upside, at -39%, 4017 screens richer than that median.

Key figures & financial health

Quality Score breakdown

About the company

Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments.

Full company description

Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments. It provides various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services. The company also operates AIRS, anesthesia, burn, diagnostics service, emergency medicine, endoscopy, intensive care, NICU, renal dialysis, rhinoplasty, and institute of robotic surgery facilities; establishes and manages pharmacies; and provides analysis and radiology laboratory, healthcare, medical education, and home health care services. In addition, it engages in the trading of pharmaceutical products, spectacles, and cosmetics; construction and contracting; wholesale and retail of medical equipment; and maintenance of IT equipment and software related services. The company was incorporated in 1978 and is based in Jeddah, the Kingdom of Saudi Arabia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Dr. Soliman Abdel Kader Fakeeh Hospital Company reported revenue of 3.1B SAR in FY2025 versus 2.0B SAR in FY2021, a compound +12.0%/yr. Reported net income was 290M SAR in FY2025, compounding −3.5%/yr from FY2021.

Is 4017 fairly valued? → Check now

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.